Pacer Advisors
ABUS icon

Pacer Advisors’s Arbutus Biopharma ABUS Stock Holding History

Pacer Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Buy
+1,706
New +$7.49K ﹤0.01% 2366

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pacer Advisors's ABUS Position: Q2 2026 in Review

Pacer Advisors opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 1,706 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2366 among its holdings.

177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Pacer Advisors held 1,706 shares of Arbutus Biopharma worth $8K as of Q2 2026.
  • Arbutus Biopharma was a new Pacer Advisors position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2366 holding.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.